...
首页> 外文期刊>World Journal of Surgical Oncology >MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6
【24h】

MicroRNA-495 inhibits proliferation of glioblastoma multiforme cells by downregulating cyclin-dependent kinase 6

机译:MicroRNA-495通过下调细胞周期蛋白依赖性激酶6抑制胶质母细胞瘤细胞的增殖

获取原文
           

摘要

Background Glioblastoma multiforme (GBM) is the most aggressive type of glioma and carries the poorest chances of survival. There is therefore an urgent need to understand the mechanisms of glioma tumorigenesis and develop or improve therapeutics. The aim of this study was to assess the possible prognostic value of cyclin-dependent kinase 6 (CDK6) and the effects of microRNA-495 (miR-495) manipulation on CDK6 expression and cell survival in glioma cells. Methods Analyses of clinical specimens from GBM patients were used. Expression of CDK6 was analyzed by real-time polymerase chain reaction (RT-PCR), Western blotting, and immunohistochemistry. Expression of CDK6 was also analyzed after over-expression of miR-495 in T98 cells; both cell proliferation and RB phosphorylation were examined. Cell proliferation, cell cycle distribution, and RB phosphorylation were also examined after knockdown of CDK6 in U87-MG and T98 cells. Results Analyses of clinical specimens from GBM patients identified that CDK6 is significantly expressed in gliomas. CDK6 antigen expression was higher in tumor cores and margins than in adjacent normal brain tissues, and higher levels of CDK6 expression in the tumor margin correlated with decreased survival. Over-expression of miR-495 in T98 cells downregulated the expression of CDK6 and inhibited retinoblastoma phosphorylation, and knockdown of CDK6 in U87-MG and T98 cells by siRNAs resulted in cell cycle arrest at the G1/S transition and inhibition of cell proliferation. Conclusions This study revealed miR-495 is down-regulated in glioma tissues. Furthermore, miR-495 regulated CDK6 expression and involved in glioma cell growth inhibition, which indicated the possible role of miR-495 in tumor progression.
机译:背景多形胶质母细胞瘤(GBM)是胶质瘤中最具侵略性的一种,其生存机会最差。因此,迫切需要了解神经胶质瘤肿瘤发生的机制并开发或改善治疗方法。这项研究的目的是评估细胞周期蛋白依赖性激酶6(CDK6)的可能的预后价值以及microRNA-495(miR-495)操纵对胶质瘤细胞CDK6表达和细胞存活的影响。方法对GBM患者的临床标本进行分析。通过实时聚合酶链反应(RT-PCR),蛋白质印迹和免疫组化分析CDK6的表达。在miR-495在T98细胞中过表达后,还分析了CDK6的表达。检查细胞增殖和RB磷酸化。在U87-MG和T98细胞中敲除CDK6后,还检查了细胞增殖,细胞周期分布和RB磷酸化。结果对来自GBM患者的临床标本进行分析后发现,CDK6在神经胶质瘤中显着表达。 CDK6抗原在肿瘤核心和边缘的表达高于相邻的正常脑组织,并且CDK6抗原在肿瘤边缘的更高表达与存活率降低相关。 miR-495在T98细胞中的过表达下调了CDK6的表达并抑制了视网膜母细胞瘤的磷酸化,而siRNA在U87-MG和T98细胞中敲除CDK6导致了细胞周期停滞在G1 / S过渡期并抑制了细胞增殖。结论这项研究表明,miR-495在神经胶质瘤组织中被下调。此外,miR-495调节CDK6表达并参与神经胶质瘤细胞生长抑制,这表明miR-495在肿瘤进展中的可能作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号